A genomic test for precision medicine in HER2+ breast cancer

The HER2DX genomic test integrates clinical and genomic information from patients with HER2+ breast cancer to estimate the risk of recurrence and response to treatment. The test, which analyzes the expression of 27 genes in a tumor sample, captures biological processes of interest for cancer progression. The results are published in eBioMedicine.

Read the full article in Genotipia.com

  • 28 de febrero de 2022
  • Sin categoría

Comments are closed.